Immunobiology of Helicobacter pylori infection

Current Opinion in Immunology

Volumn 9, Issue 4, 1997, Pages 498-503

  Telford, John L ^a   Covacci, Antonello ^a   Rappuoli, Rino ^a   Ghiara, Paolo ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BACTERIAL IMMUNITY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HELPER CELL; IMMUNOBIOLOGY; INCUBATION TIME; INFLAMMATION; NONHUMAN; REVIEW;

EID: 0030827244     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80101-X     Document Type: Article

References (52)

1. Blaser MJ. Helicobacter pylori: microbiology of a 'slow' bacterial infection. Trends Microbiol. 1:1993;255-260.
2. Blaser MJ, Parsonnet J. Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 94:1994;4-8.
3. Fiocca R, Luinetti O, Villani L, Chiaravalli AM, Capella C, Solcia E. Epithelial cytotoxicity, immune responses, and inflammatory components of Helicobacter pylori gastritis. Scand J Gastroenterol. 29:1994;11-21.
4. Telford JL, Covacci A, Ghiara P, Montecucco C, Rappuoli R. Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential for new therapies and vaccines. Trends Biotechnol. 12:1994;420-426.
5. Ghiara P, Marchetti M, Blaser MJ, Tummuru MKR, Cover TL, Segal ED, Tompkins LS, Rappuoli R. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease. Infect Immun. 63:1995;4154-4160.
6. Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 267:1995;1655-1658.
7. Censini S, Lange C, Xiang ZY, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. of outstanding interest Proc Natl Acad Sci USA. 93:1996;14648-14653 Discovery of the 40 kilobase pairs cag pathogenicity island of H. pylori Type I strains and the demonstration of its role in enhancing virulence, including its pivotal role in the induction of inflammation through the induction of IL-8 synthesis, which is a major pro-inflammatory cytokine. This paper also describes the genetic basis for the differences between the disease-associated Type I strains and the much less pathogenic Type II strains.
8. Harris PR, Cover TL, Crowe DR, Orenstein JM, Graham MF, Blaser MJ, Smith PD. Helicobacter pylori cytotoxin induces vacuolation of primary human mucosal epithelial cells. Infect Immun. 64:1996;4867-4871.
9. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology. 112:1997;92-99.
10. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, Rappuoli R. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA. 90:1993;5791-5795.
11. Tummuru MK, Cover TL, Blaser MJ. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect Immun. 61:1993;1799-1809.
12. Xiang Z, Bugnoli M, Rappuoli R, Covacci A, Ponzetto A, Crabtree JE. Helicobacter pylori: host responses in peptic ulceration. Lancet. 341:1993;900-901.
13. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55:1995;2111-2115.
14. Xiang ZY, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, Covacci A. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun. 63:1995;94-98.
15. Crabtree JE, Peichl P, Wyatt JI, Stachl U, Lindley U. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol. 37:1993;65-70.
16. Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther. 10:1996;29-37.
17. Basso D, Scrigner M, Toma A, Navaglia F, DiMario F, Rugge M, Plebani M. Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res. 26:1996;207-210.
18. Harris PR, Mobley HLT, Perez-Perez GI, Blaser MJ, Smith PD. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production. Gastroenterology. 111:1996;419-425.
19. Di Tommaso A, Xiang ZY, Bugnoli M, Pileri P, Figura N, Bayeli PF, Rappuoli R, Abrignani S, De Magistris MT. Helicobacter pylori-specific CD4(+) T-cell clones from peripheral blood and gastric biopsies. Infect Immun. 63:1995;1102-1106.
20. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. of special interest J Immunol. 156:1996;4729-4738 See annotation [21].
21. Mohammadi M, Redline R, Nedrud J, Czinn S. Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. of special interest Infect Immun. 64:1996;238-245 This paper, along with [20], introduces the concept of a role for a Th1 type of immune response in the induction of disease in an animal model of Helicobacter infection.
22. D'Elios MM, Manghetti M, DeCarli M, Costa F, Baldari CT, Burroni D, Telford JL, Romagnani S, Del Prete G. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. of outstanding interest J Immunol. 158:1997;962-967 This paper shows for the first time in humans that H. pylori specific T cell clones with a predominant Th1 phenotype can be more frequently isolated from patients with peptic ulcer disease than from patients with mild gastritis.
23. Karttunen RA, Karttunen TJ, Yousfi MM, Elzimaity HMT, Graham DY, Elzaatari FAK. Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with Helicobacter pylori. Scand J Gastroenterol. 32:1997;22-27.
24. Negrini R, Lisato L, Zanella I, Cavazzini L, Gullini S, Villanacci V, Poiesi C, Albertini A, Ghielmi S. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology. 101:1991;437-445.
25. Aspinall GO, Monteiro MA, Pang H, Walsh EJ, Moran AP. O antigen and the lipopolysaccharide of Helicobacter pylori NCTC 11637. Carbohyd Lett. 1:1994;151-156.
26. y in the induction of autoimmunity. It also reports that chronic H. pylori infection in mice elicits serum antibodies against these antigens.
27. Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A, Cesari P, Graffeo M, Vaira D, Franzin G. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. of outstanding interest Gastroenterology. 111:1996;655-665 The association of the molecular mimicry between H. pylori and antigens of the gastric epithelium with the occurrence of gastric atrophy is described. The presence of cross-reactive antibodies correlates with the degree of inflammation and with the severity of gastric atrophy. Gastric atrophy is a histopathological condition that is strongly associated with the subsequent malignant transformation that leads to gastric adenocarcinoma.
28. y structures is correlated with the capacity of the strain to express the antigen CagA. Induction of autoreactive antibodies could contribute to worsen and amplify the gastric inflammation that occurs during infections with Type I strains of H. pylori. This study is therefore a further demonstration of the enhanced virulence potential conferred by the cag PAI of the type I strains.
29. Appelmelk BJ, Negrini R, Moran AP, Kuipers EJ. Molecular mimicry between Helicobacter pylori and the host. of outstanding interest Trends Microbiol. 5:1997;70-73 An excellent review on antigen mimicry by H. pylori.
30. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 325:1991;1127-1231.
31. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman HJ, Friedman GD. Helicobacter pylori infection and gastric lymphoma. New Engl J Med. 330:1994;1267-1271.
32. Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol Suppl. 142:1988;44-49.
33. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 342:1993;575-577.
34. Carlson SJ, Yokoo H, Vanagunas A. Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori. of special interest JAMA. 275:1996;937-939 A very good paper showing the progression of gastritis into malignant low grade B cell lymhoma. The observations reported in this paper support the association between H. pylori infection and the development of a gastric monoclonal B cell lymphoma. This lesion appears to develop in the setting of H. pylori gastritis and progresses through lymphoid hyperplasia which is followed by the lymphoma. The process is initially driven by H. pylori antigens and thereafter becomes autonomous, as genetic damage accumulates as a consequence of chronic inflammation.
35. Hussell T, Isaacson PG, Crabtree JE, Dogan A, Spencer A. Immunoglobulin specificity of low grade B cell gastric lymphoma of mucosa associated lymphoid tissue. Am J Pathol. 142:1993;285-292.
36. Greiner A, Marx A, Heesemann J, Leebmann J, Schumausser B, Mullerhermelink HK. Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. of special interest Lab Invest. 70:1994;572-578.
37. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 178:1996;122-127 Demonstration of H. pylori specific T cells in low-grade B cell lymphoma indicating a causal role for H. pylori in this disease.
38. Schutze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut. 36:1995;831-833.
39. Chen M, Lee A, Hazell S. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet. 339:1992;1120-1121.
40. Michetti P, Corthesy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M, Bille J, Kraehenbuhl JP, Saraga E, Blum AL. Immunization of BALB/c mice against Helicobacter felis infection with H. pylori urease. Gastroenterology. 107:1994;1002-1011.
41. Ferrero RL, Thiberge JM, Huerre M, Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp: evidence of protection in a mouse model of gastric infection. Infect Immun. 62:1994;4981-4989.
42. Ferrero RL, Thiberge J-M, Kansau I, Wuschner N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 92:1995;6499-6503.
43. Radcliff FJ, Chen MH, Lee A. Protective immunization against Helicobacter stimulates long term immunity. Vaccine. 14:1996;780-784.
44. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney AC, Haas R, Kraehenbuhl JP, Blum AL, Michetti P. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. of outstanding interest Gastroenterology. 109:1995;115-121.
45. Cuenca R, Blanchard TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK, Redline RW. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 110:1996;1770-1775 This paper describes the eradication of a natural infection of H. mustelae in ferrets using a subunit vaccine composed of recombinant H. pylori urease plus cholera toxin.
46. Lee CK, Weltzin R, Thomas WD, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 172:1995;161-172. of outstanding interest.
47. Bogstedt AK, Nava S, Wadstrom T, Hammarstrom L. Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin Exp Immunol. 105:1996;202-204 This paper describes the lack of increase in incidence and severity of H. pylori infection in humans carrying IgA deficiency, which is one of the most common innate immunodeficiency conditions in man.
48. Nedrud T, Blanchard S, Czinn GR, Harriman GR. Orally immunized IgA-deficient mice are protected against H. felis infection [abstract]. of outstanding interest Gut. 39:1996;A45 So far only an abstract, but a paper to look for. It describes the lack of the role of the secretory IgA system in the protective effector mechanism elicited by mucosal vaccination against Helicobacter infection.
49. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, Okahashi N, Yamamoto M, Kiyono H, Bluethmann H, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol. 155:1995;4621-4629.
50. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, Hamada S, Clements JD, Bost KL, McGhee JR. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile toxin. J Infect Dis. 173:1996;627-635.
51. Covacci A, Falkow S, Berg DE, Rappuoli R. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori. of outstanding interest Trends Microbiol. 5:1997;205-208 This review describes the current knowledge on the molecular basis of evolution of virulence in H. pylori Type I virulent strains through the inheritance of DNA insertions that contain genes associated with disease.
52. Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. of special interest Lancet. 347:1996;1630-1631 The first official report of a subunit vaccine Phase I trial performed last year with purified recombinant enzymatically inactive urease. 12 nonsymptomatic H. pylori infected volunteers were randomized to receive, orally, either 60mg of urease or a placebo once weekly for 4 weeks. Urease was well tolerated and no major adverse reactions occurred. Mean gastritis score assessed on bioptic specimens was not altered by treatment and only minor erosions were observed in three volunteers receiveing urease and in one receiving the placebo. As expected, however, as no mucosal adjuvant was used in this trial, all volunteers remained infected.